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Abstract
Background: Topoisomerase IIα has been shown to be down-regulated in doxorubicin-resistant
cell lines. The specificity proteins Sp1 and Sp3 have been implicated in regulation of topoisomerase
IIα transcription, although the mechanism by which they regulate expression is not fully
understood. Sp1 has been shown to bind specifically to both proximal and distal GC elements of
the human topoisomerase IIα promoter in vitro, while Sp3 binds only to the distal GC element
unless additional flanking sequences are included. While Sp1 is thought to be an activator of human
topoisomerase IIα, the functional significance of Sp3 binding is not known. Therefore, we sought
to determine the functional relationship between Sp1 and Sp3 binding to the topoisomerase IIα
promoter in vivo. We investigated endogenous levels of Sp1, Sp3 and topoisomerase IIα as well as
binding of both Sp1 and Sp3 to the GC boxes of the topoisomerase IIα promoter in breast cancer
cell lines in vivo after short term doxorubicin exposure.
Results: Functional effects of Sp1 and Sp3 were studied using transient cotransfection assays using
a topoisomerase IIα promoter reporter construct. The in vivo interactions of Sp1 and Sp3 with the
GC elements of the topoisomerase IIα promoter were studied in doxorubicin-treated breast
cancer cell lines using chromatin immunoprecipitation assays. Relative amounts of endogenous
proteins were measured using immunoblotting. In vivo DNA looping mediated by proteins bound
at the GC1 and GC2 elements was studied using the chromatin conformation capture assay. Both
Sp1 and Sp3 bound to the GC1 and GC2 regions. Sp1 and Sp3 were transcriptional activators and
repressors respectively, with Sp3 repression being dominant over Sp1-mediated activation. The
GC1 and GC2 elements are linked in vivo to form a loop, thus bringing distal regulatory elements
and their cognate transcription factors into close proximity with the transcription start site.
Conclusion:  These observations provide a mechanistic explanation for the modulation of
topoisomerase IIα and concomitant down-regulation that can be mediated by topoisomerase II
poisons. Competition between Sp1 and Sp3 for the same cognate DNA would result in activation
or repression depending on absolute amounts of each transcription factor in cells treated with
doxorubicin.
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Background
Topoisomerases are ubiquitous enzymes that alter DNA
topology by cleavage and religation of the DNA. Human
topoisomerase II exists as two isoforms, known as topoi-
somerase IIα (174 kDa) and topoisomerase IIβ (182
kDa), which are essential for a number of nuclear proc-
esses, including chromosome condensation, chromatid
separation, and relief of torsional stress during DNA rep-
lication and transcription [1]. These topoisomerases have
been shown to be targeted by common anti-cancer drugs
known as topoisomerase poisons, including acridines,
anthracyclines, and actinomycins as they stabilize the
enzyme-mediated double-stranded breaks in the DNA [2].
Drug sensitivity to the topoisomerase II poisons is
dependent on high levels of topoisomerase II in addition
to the presence of the drug, while drug resistance has been
correlated with low levels of the enzyme. Doxorubicin has
been shown to be most effective when cells are rapidly
proliferating and expressing high levels of topoisomerase
IIα, the critical nuclear enzyme in maintaining correct
DNA topology, which is vital for cell function and sur-
vival. Many factors have been implicated in the develop-
ment of resistance to chemotherapeutic drugs but the
down-regulation of topoisomerase II is believed to be an
important mechanism underlying the acquired drug
resistance [3-5]. The molecular mechanisms linking drug
treatment and down-regulation of topoisomerase II
expression are incompletely understood. For example it is
not known whether the down-regulation of topoisomer-
ase II expression is the result of early changes in expres-
sion of key transcription factors or more subtle effects that
occur over a longer time course.
The human topoisomerase IIα promoter has five func-
tional CCAAT boxes (ICB1-5) and two GC boxes [6].
CCAAT boxes are customarily flanked by at least one func-
tionally important promoter element. In the case of the
human topoisomerase IIα promoter ICB1 and ICB5 are
flanked by GC1 and GC2 respectively. GC boxes are the
second most frequent element in promoters and tend to
be present in multiple copies. In promoters where multi-
ple GC boxes are present, it is common for each GC box
to have a different function according to its position with
respect to the transcription start point and other flanking
elements.
Within the human topoisomerase IIα promoter, GC1 is
contained in the minimal promoter [6], whereas GC2 is
distal to this region. Mutations in GC1 have shown no
marked decrease in topoisomerase IIα activity, however in
resistant cells a mutation in GC1 has been shown to
increase promoter activity (reviewed in [7]).
Although some promoters have multiple GC boxes, it has
been shown that a single Sp1 binding site is sufficient to
stimulate promoter activity [8]. Sp1 is commonly known
as a transcriptional activator and has been shown to be
able to up-regulate transcription in a variety of promoters
including topoisomerase IIα [9]. Sp1-mediated transcrip-
tional activation depends on 3 zinc finger structures
responsible for DNA binding, and at least one of two Q-
rich regions (or activation motifs) that are required for
protein/protein interactions and coincident synergistic
transactivation [10].
Sp3 is similar to Sp1 in a number of ways: it is ubiqui-
tously expressed in mammalian cells, has increased DNA
binding affinity when phosphorylated, and has the ability
to compete with the same target sequences with similar
binding affinities due to similar DNA binding domains.
The major difference between the two transcription fac-
tors is that Sp3 is bifunctional, possessing the ability to act
not only as a repressor, but also as an activator. The repres-
sive function of Sp3 has been attributed to a region near
the N-terminus, which acts as a transcriptional repressor
of several activators. It is thought that promoters with a
single binding site can be activated by Sp3, but those with
multiple binding sites respond weakly to Sp3 or not at all
[11]. While Sp3 may be able to form homo-oligomers
synergistic transactivation does not occur [12].
Important chromosomal activities and the properties of
local chromatin structure affect gene expression, origin fir-
ing, and DNA replication [13]. First described by Dekker
et al., 2002 [14], chromosome conformation capture
allows the analysis of spatial organization of chromo-
somes. This method affords high resolution and specific
definition of chromatin conformation. DNA looping has
been suggested in earlier reports [9,15] to have important
implications in the functional properties of protein-pro-
moter interactions particularly in the case of Sp1/Sp3
interactions with the GC1 and GC2 regions in the human
topoisomerase IIα promoter.
In this study we explore the regulation of the human
topoisomerase IIα promoter in vivo using MDA MB 231
cells in the early stages of treatment with doxorubicin, a
cytotoxic drug commonly used to treat breast cancer. We
show that Sp3 has a dominant repressive effect on Sp1-
mediated activation. With lower levels of topoisomerase
IIα evident in drug treated breast cancer cells, these data
suggest that Sp3 may play a vital role in the development
of resistance to chemotherapy and supports earlier work
that suggested Sp3 was upregulated in etoposide/tenipo-
side-resistant KB cell lines [16]. We also show that GC1
and GC2 are indeed on a DNA loop indicating that both
GC regions play an important part in the regulation of the
promoter.BMC Molecular Biology 2007, 8:36 http://www.biomedcentral.com/1471-2199/8/36
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Results
Transcription factors Sp1 and Sp3 bind to both GC1 and 
GC2
Chromatin immunoprecipitation analysis using MDA MB
231 cells shows that both the GC1 and GC2 elements of
the topoisomerase IIα promoter are occupied by both Sp1
and Sp3 in vivo (Figures 1 and 2). Fold enrichment values
are presented as "relative occupancy units" and were cal-
culated by subtracting background immunoprecipitation
efficiencies from observed immunoprecipitation efficien-
cies. Input was arbitrarily set at 1 after background correc-
tion. For GC1 binding, the Sp1 control (0 hour treatment)
was found to have 20 occupancy units over the input,
while the 2 and 24 hour treatments were shown to have
17 and 4 occupancy units respectively. Association of Sp3
with GC1 at the control (0 hour) and 2 hour treatments is
comparable to that of Sp1 association, with 17 and 20
occupancy units respectively. Sp3 data at the 24 hour time
point, on the other hand, show higher relative protein
occupancy. Sp1 occupancy units at GC2 for control (0
hour), 2 hour, and 24 hour treatments were 11, 7, and 5
respectively. Sp3 protein occupancy at GC2 showed a
reverse trend for the same treatment times with 3, 10, and
13 units.
These data suggest that more Sp1 and Sp3 protein can
bind to GC1 in vivo than to GC2. When exposed to doxo-
rubicin, there is no significant change in occupancy at
GC1 for either Sp1 or Sp3 at 0 hour and 2 hours after
exposure (insets of Figure 1 and Figure 2). There is how-
ever, a significant difference between Sp1 and Sp3 occu-
pancy 24 hours after exposure, with the association
between Sp3 and GC1 being 6.75 fold greater than Sp1
association with GC1. The occupancy by Sp1 and Sp3 of
GC2, however, is decreased by 20% and 50 % respectively
after 2 hours of drug exposure and by 50 % and 100%
respectively after 24 hours of drug exposure (Figure 1 and
Figure 2). While we cannot rule out the presence of a
larger template containing both the GC1 and GC2 ele-
ments, these differences in occupancy suggest that sepa-
rated DNA elements were in fact immunoprecipitated and
support the conclusion that both Sp1 and Sp3 bind to
each of GC1 and GC2 in vivo.
Sp1 and Sp3 act as transcriptional activator and repressor 
respectively
MDA MB 231 cells were transiently transfected with the
luciferase reporter vector pGL3Basic incorporating the -
617 promoter of human topoisomerase IIα [6,17]. This
region contains both the distal GC2 element and the prox-
Occupancy of Sp3 at GC2 of the topoisomerase IIα pro- moter increases after doxorubicin treatment Figure 2
Occupancy of Sp3 at GC2 of the topoisomerase IIα pro-
moter increases after doxorubicin treatment. ChIP analysis 
was carried out using MDA MB 231 breast cancer cells. Cells 
were exposed to a single dose of doxorubicin (5 µM) for 1 
hour and cell extracts were taken at 0 hr (control), 2 hr and 
24 hr after initial exposure. Values were calculated as in the 
legend for Figure 1 and represent the average and standard 
error of the fold enrichment in three experiments carried 
out in triplicate. The corresponding gel photograph (inset) 
shows PCR products from real time PCR of Sp1 or Sp3 bind-
ing to GC2 in unexposed (0 hr) and exposed (2 h and 24 h) 
cells. I indicates input control. Results are expressed as ± 
SEM where n = 9, *** p < 0.001, ** p < 0.01, and * p < 0.05.
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Occupancy of Sp1 at GC1 of the topoisomerase IIα pro- moter decreases after doxorubicin treatment Figure 1
Occupancy of Sp1 at GC1 of the topoisomerase IIα pro-
moter decreases after doxorubicin treatment. ChIP analysis 
was carried out using MDA MB 231 breast cancer cells. Cells 
were exposed to a single dose of doxorubicin (5 µM) for 1 
hour and cell extracts were taken at 0 hr (control), 2 hr and 
24 hr after initial exposure. Each value represents the aver-
age and standard error of the fold enrichment in three 
experiments carried out in triplicate. Fold enrichment values 
are "relative protein occupancies" calculated by subtracting 
background levels from observed immunoprecipitation effi-
ciencies. The corresponding gel photograph (inset) shows 
PCR products from real time PCR of Sp1 or Sp3 binding to 
GC1. in unexposed (0 hr) and exposed (2 h and 24 h) cells. I 
indicates input control. Results are expressed as ± SEM 
where n = 9, *** p < 0.001, ** p < 0.01, and * p < 0.05.
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imal GC1 element. In each assay, the pCMV Sport β-galac-
tosidase vector was used as a control for transfection
efficiency. The effects of Sp1 and Sp3 on transcription
were tested by co-transfecting increasing amounts of Sp1
and Sp3 expression vectors respectively (Figure 3). Sp1
has been shown previously to be a transcriptional activa-
tor in both HeLa [9] and MDA MB 231 [18]. Figure 3
clearly shows Sp3 acts as a transcriptional repressor of
human topoisomerase IIα by decreasing expression in a
dose-dependent manner by approximately 60% at the
highest concentration used.
Since Sp1 and Sp3 can bind to both GC elements in vivo
as shown in figures 1 and 2 we sought to determine
whether one had a dominant functional effect over the
other. Transient transfections using a range of concentra-
tions of Sp1 and Sp3 were carried out. These experiments
show that the repressive effect of Sp3 can only partially be
overcome by Sp1 (Figure 4) where with equal quantities
of added Sp1 and Sp3, transcriptional activity is
approaching control values. In addition, the activating
effect of Sp1 is completely abolished by Sp3 where with
even a 4:1 ratio of Sp1:Sp3 the transcriptional activity is
the same as the control (Figure 5). These results suggest
that Sp1 and Sp3 are activators and repressors respectively
of human topoisomerase IIα in vivo. More importantly
they suggest that Sp3 is functionally dominant over Sp1.
Sp3 transcriptional repression is dominant over activation by  Sp1 Figure 5
Sp3 transcriptional repression is dominant over activation by 
Sp1. All transfections were performed in triplicate with 1.0 
µg of -617 wt topoisomerase IIα reporter plasmid and 1 µg 
of pCMV Sport β-galactosidase control vector. Relative luci-
ferase activity was calculated by arbitrarily setting the control 
(no added Sp1 or Sp3) to 100%. Results are expressed as ± 
SEM where n = 9, *** p < 0.001, ** p < 0.01, and * p < 0.05
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Sp1 and Sp3 are antagonistic at the topoisomerase IIα pro- moter Figure 3
Sp1 and Sp3 are antagonistic at the topoisomerase IIα pro-
moter. All transfections were performed in triplicate with 1.0 
µg of -617 wt topoisomerase IIα reporter plasmid and 1 µg 
of pCMV Sport β-galactosidase control vector. Relative luci-
ferase activity was calculated by arbitrarily setting the control 
(0 µg, containing only topoisomerase IIα reporter plasmid 
and pCMV Sport β-galactosidase control vector) to 100%. 
Results are expressed as ± SEM where n = 9, *** p < 0.001, 
** p < 0.01, and * p < 0.05.
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Sp3 maintains transcriptional repression in the presence of  Sp1 Figure 4
Sp3 maintains transcriptional repression in the presence of 
Sp1. All transfections were carried out in triplicate with 1.0 
µg of -617 wt topoisomerase IIα reporter plasmid and 1 µg 
of pCMV Sport β-galactosidase control vector. Relative luci-
ferase activity was calculated by arbitrarily setting the control 
(no added Sp1 or Sp3) to 100%. Results are expressed as ± 
SEM where n = 9, *** p < 0.001, ** p < 0.01, and * p < 0.05
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Expression of endogenous topoisomerase II alpha, Sp1 and 
Sp3 in doxorubicin exposed breast cancer cells
Semi-quantitative immunoblotting of cell extracts was
carried out and the amounts of topoisomerase IIα, Sp1,
and Sp3 were expressed as a percentage relative to tubulin
and normalised to the control (0 hr) which was arbitrarily
set at 100%. The results showed decreased amounts of
topoisomerase IIα and Sp1 at 2 and 24 hours after expo-
sure when compared to unexposed (0 hr) control cells.
Amount of Sp3 increased in relation to the control (Figure
6). These results clearly show a significant difference
between the control and drug-exposed cells for all pro-
teins at each time point and suggest that the changes in
expression of Sp1, Sp3, and topoisomerase IIα are the
result of exposure to doxorubicin. The molecular mecha-
nism responsible for the altered expression of both Sp1
and Sp3, however, is uncertain.
GC1 and GC2 exist in close proximity on looped DNA in 
HeLa cells
Chromosome conformation capture results (Figure 7)
show that GC1 and GC2 are located within close spatial
proximity on the human topoisomerase IIα promoter in
vivo as suggested previously [9,15]. The results show an
uncut PCR product representing ligated promoter in lane
2, with a size of 429 bp. This is in comparison to the uncut
PCR product produced from untreated genomic DNA in
lane 4 (571 bp). Digestion of the ligation product (lane 1)
yields two fragments (123 and 306 bp), while digestion of
the genomic DNA product (lane 3) yields three fragments
(123, 142, and 306 bp) as predicted from the genomic
DNA sequence. These results suggest that the GC1 and
GC2 elements are normally (in the absence of drug) posi-
tioned in vivo close to the transcription start point by vir-
tue of the interactions between Sp1 and/or other factors
with the cognate DNA.
The proximal topoisomerase IIα promoter forms a loop  between GC1 and GC2 Figure 7
The proximal topoisomerase IIα promoter forms a loop 
between GC1 and GC2. A ligation product (429 bp) was 
detected by PCR (lane 2) after completion of the 3C assay. 
Digestion of ligated product (lane 1) with BSu36 I yielded two 
fragments (123 bp and 306 bp). The PCR product from the 
uncut genomic DNA control (lane 4) was 571 bp in size. 
When digested with BSu36 I, genomic DNA product (lane 3) 
yielded three fragments (123, 306 and 142 bp) as predicted 
from the DNA sequence.
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Endogenous topoisomerase IIα decreases concomitantly  with decreased Sp1 and Sp3 after treatment with doxoru- bicin Figure 6
Endogenous topoisomerase IIα decreases concomitantly 
with decreased Sp1 and increased Sp3 after treatment with 
doxorubicin. (A) Topoisomerase IIα; (B) Sp1; (C) Sp3; (D) 
tubulin control, at time points 0 hours (i), 2 hours (ii), and 24 
hours (iii) after exposure to doxorubicin in MDA MB 231 
cells. The three proteins bracketed in C represent the iso-
forms of Sp3 produced from alternative start codons. Results 
show the average of three experiments carried out in tripli-
cate and are expressed as ± SEM where n = 9, *** p < 0.001, 
** p < 0.01, and * p < 0.05. The insert shows one indicative 
immunoblot.
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Discussion
While it has been documented that Sp1 binds to GC rich
regions in the topoisomerase IIα promoter [9] there has
been no study reported to date that addresses Specificity
protein/GC interactions at the topoisomerase IIα pro-
moter in vivo. Here we show, for the first time, that both
Sp1 and Sp3 bind to both the GC1 and GC2 elements of
the topoisomerase IIα promoter in vivo and there is a
greater occupancy of both proteins at GC1 than at GC2.
These observations implicate GC1 as having a major role
in basal transcription of topoisomerase IIα while GC2
may function in a more modulatory capacity. We have
previously shown that Sp1 acting at the GC2 element may
repress basal transcription via a putative interaction at the
ICB1 and GC1 elements either by direct interaction or the
recruitment of other regulatory proteins [9]. These find-
ings suggested that proteins bound to the GC2 element
may act as repressors, which is supported by the current
data from ChIP analysis indicating that both Sp1 and Sp3
can interact in vivo with GC2 (Figures 1 and 2). Putative
interactions with other transcriptional modulators how-
ever, cannot be ruled out. Chromosome conformation
capture assays used in this study support the findings sug-
gested by Mastrangelo et al., 1991 [15], that there is a
physical loop formed which results in a strongly increased
concentration of transcriptional modulators at the proxi-
mal promoter. It has been reported that transcription
activities are related to the overall spatial arrangements
between protein transcription factors and their cognate
DNA elements [19-22]. We show that Sp1 and Sp3 bind
to both GC1 and GC2 in vivo and are likely to modulate
transcription due to both DNA/protein (Sp1 and/or Sp3)
interactions and protein/protein interactions between
Sp1 facilitated by DNA looping between the GC1 and
GC2 elements of the topoisomerase IIα promoter. As Sp3
does not form multimers or interact with Sp1 [12], the
repressive effect of Sp3 is likely to be due to its dominant
effect over Sp1. Our data suggest that Sp3 can displace Sp1
from either or both GC1 and GC2 and this would be likely
to open the chromatin loop.
We have previously shown that Sp1 can up-regulate tran-
scription of topoisomerase IIα [9,18] and this current
study supports Sp1 as a transcriptional activator of topoi-
somerase IIα. These findings are consistent with other
work, which has shown that in the rat topoisomerase IIα
promoter, Sp1 is a transcriptional activator at the GC2 ele-
ment, which is spatially equivalent to the GC1 element of
the human topoisomerase IIα promoter [23].
More importantly we show for the first time that Sp3 is a
transcriptional repressor of topoisomerase IIα that is func-
tionally dominant over Sp1. Immunoblotting results indi-
cate that changes in expression levels of these proteins
occur with exposure to chemotherapeutic agents. Other
reports suggest that in some promoter contexts both Sp1
and Sp3 have both activator [24-27] and repressor func-
tions [28,29]. Moreover, the repressive functions of Sp3
transcription factors have recently been implicated in
breast cancer cell lines [30,31]. Reduced Sp3 RNA levels in
merbarone-resistant human leukemic CEM cells have
been shown to correlate with a down-regulation of topoi-
somerase IIα protein levels [32]. These authors also
showed that co-transfection of Sp3 induced topoisomer-
ase IIα promoter activity in drug sensitive CEM cells in a
dose dependent manner. Conversely, Sp3 levels were
shown to be elevated in etoposide/teniposide-resistant KB
cells, and this elevation correlated with a decrease in
topoisomerase IIα activity [16]. Taken together, these
observations suggest that Sp3 is normally a transcriptional
repressor of topoisomerase IIα, but its effects are likely to
be cell type specific.
In co-transfection studies using Sp1 and/or Sp3 expres-
sion plasmids other reports have shown that while Sp1
stimulated, Sp3 repressed Sp1-mediated transactivation of
human transcobalanin II (TC II) transcription [33]. In
functional analyses using Drosophila SL-2 cells, Sp1
expression can drive transcription from the elastin proxi-
mal promoter, while co-expression of Sp3 results in a
repression of Sp1 activity [34]. Functional assays have sug-
gested that TGF-beta1 inhibition of COL2A1 gene tran-
scription in rabbit articular chondrocytes is mediated by
an increase of the Sp3/Sp1 ratio and by the repression of
Sp1 transactivating effects on that gene [35]. These
authors found that both proteins bind to the same sites of
the c-myc promoter. Co-transfection experiments, in
mammalian and insect cells, indicated that Sp1 trans-acti-
vated the c-myc promoter, whereas Sp3 did not. In addi-
tion, enforced expression of Sp3 repressed Sp1-mediated
activation of c-myc [11]. These data support our findings
for the transcriptional regulation of human topoisomer-
ase IIα and suggest that Sp3 may be a common modulator
of Sp1-dependent transcriptional activation.
The dominant repressive activity of Sp3 over Sp1 has
important implications for the expression of topoisomer-
ase IIα in doxorubicin-based chemotherapy. Our results
show that in unexposed and drug exposed cells, Sp1 and
Sp3 both interact with the topoisomerase IIα promoter at
the GC1 and GC2 elements in vivo. We have previously
shown an interaction between both Sp1 and Sp3 with an
isolated GC2 element in vitro but Sp3 was only able to
bind to a composite element containing both ICB1 and
GC1 [9]. This suggests more complex interactions may
occur between DNA and protein in vivo and conformation
of the chromatin in the topoisomerase IIα promoter may
have a critical role in allowing access and binding of tran-
scription factors. In addition, while both Sp1 and Sp3 are
able to interact with GC2 in untreated cells, occupancy atBMC Molecular Biology 2007, 8:36 http://www.biomedcentral.com/1471-2199/8/36
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this site is significantly less than at GC1. We, and others
have shown that topoisomerase IIα expression levels are
reduced in drug resistant breast cancer cells. Co-transfec-
tion assays have shown that Sp3 negatively impacts Sp1-
mediated activation. Sp1/Sp3 co-transfection results, cou-
pled with the results of Sp3 ChIP assays therefore suggest
that Sp3 plays a critical role in the down-regulation of
topoisomerase IIα in drug treated breast cancer cells. We
have previously shown that the absolute amounts of Sp3
in some doxorubicin-resistant cell lines with reduced
topoisomerase IIα did not alter significantly, while Sp1
levels were significantly reduced [9]. Taken together these
data support the suggestion that the ratio of Sp1/Sp3 is
likely to be a critical factor in determining the level of
expression of topoisomerase IIα and hence sensitivity to
doxorubicin treatment.
We have previously suggested that DNA looping at the
topoisomerase IIα promoter may be involved in deter-
mining expression levels of the gene [9,36]. The results
presented here demonstrate that a DNA loop can be
formed at the topoisomerase IIα promoter between the
GC1 and GC2 elements. When Sp1 levels are sufficiently
high, it is likely that occupancy at both GC1 and GC2
occurs to form a multi-protein/DNA complex and maxi-
mal transcription. Drug treatment reduces Sp1 levels and
subsequently causes a reduction in binding at both GC1
and GC2. At the same time Sp3 levels rise and while occu-
pancy at GC1 does not change markedly, there is a signif-
icant increase of occupancy at GC2 by Sp3. Sp3, in
preference to Sp1, bound at both GC1 and GC2 would
cause opening of the chromatin loop (because Sp3 does
not self-associate as does Sp1) and a concomitant
decrease in topoisomerase IIα expression. This correlates
with the up-regulation of expression we observed previ-
ously in transient transfection assays using the -617 topoi-
somerase IIα promoter carrying a point mutation in the
GC2 element, that would preclude binding of Sp3 [9].
Where ratios of Sp1/Sp3 are high a multiprotein/DNA
complex is likely to form, with accompanying high levels
of expression (Figure 8A). As the ratio of Sp1/Sp3 drops
with drug treatment Sp3 will start to replace Sp1 at both
GC1 and GC2 with less likelihood of forming a chromatin
loop (Figure 8B and 8C). Absolute levels of transcription
will then depend upon the ratio of Sp1/Sp3 in the cell but
as Sp3 is dominant over Sp1, relatively small increases in
Sp3 levels or decreases in Sp1/Sp3 ratio could result in
reduced transcription of topoisomerase IIα. As these
effects occur early in drug treatment, the expression levels
of Sp1 and Sp3 may be the primary determinants of topoi-
somerase IIα expression in the early stages of chemother-
apy. Initial low protein levels of topoisomerase IIα as
shown in Figure 6, would be predicted to result in fewer
cleavable complexes allowing effective DNA repair to take
place, consequently leading to drug resistance in the
longer term.
Conclusion
In summary, we have shown that reduced transcription of
topoisomerase IIα associated with doxorubicin treatment
is likely to be due to the reduction in Sp1 that has been
shown to occur at cell cycle arrest [36] allowing Sp3 to
exert its dominant repressive effect. This has important
implications for chemotherapy using drugs that target
both topoisomerase IIα and cause cell cycle arrest. If the
Sp1/Sp3 ratio could be manipulated such that topoi-
somerase IIα transcription remains at high levels, the
drugs classed as topoisomerase II poisons may be more
effective. Alternatively, assessment of Sp1/Sp3 ratios in
cancer cells may provide an additional prognostic marker
for treatment with drugs like doxorubicin that cause cell
cycle arrest.
Methods
Cell lines
Breast cancer (MDA MB 231) and cervical cancer (HeLa)
cells were obtained from ATCC and maintained on mini-
mum essential medium (OPTI-MEM) supplemented with
non-essential amino acids (Sigma-Aldrich Pty Ltd., Castle
Hill, NSW, Australia), 1% penicillin/streptomycin (Gibco
BRL/Invitrogen) and 4% (v/v) fetal calf serum (Gibco
BRL/Invitrogen).
Transient transfection assays
Transient transfection assays were carried out in 12-well
tissue culture plates with cells at approximately 60% con-
fluence using 1 µg of reporter vector (topoisomerase IIα-
617pGL3Basic [9], 1 µg of pCMV Sport β-galactosidase
Transcriptional modulation of topoisomerase IIα facilitated  by DNA looping Figure 8
Transcriptional modulation of topoisomerase IIα facilitated 
by DNA looping. (A) High levels of Sp1 and the formation of 
Sp1 multimers results in increased transcriptional activity of 
the topoisomerase IIα promoter. (B) A repressive effect on 
promoter activity when Sp1/3 levels are equal as Sp1 can no 
longer form protein/protein interactions because of Sp3 
occupancy at either GC1 or GC2. (C) Higher Sp3 levels 
show a dominant repressive effect of promoter activity as 
most GC1 and GC2 elements are occupied by Sp3.
A.
GC1
GC1
GC2
GC2
Sp3-induced repression
Sp1-induced activation
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control vector (Invitrogen) and various amounts of Sp1,
and/or Sp3, co-expression vectors using Metafectene
(Biontex) transfection reagent according to the manufac-
turer's instructions. The Sp1 (EF1a/Sp1) co-expression
vector was a gift from Dr Merlin Crossley, University of
Sydney, Australia) and the Sp3 vector (SPR-2) was from
Dr Guntram Suske, Institut fur Molekularbiologie und
Tumorforschung, Philipps-Universitat Marburg, Ger-
many. Extracts from cells were harvested 24 hours after
transfection and assayed for luciferase activity using a
Luciferase Assay Kit (Promega) and FLUOStar galaxy
microplate reader (BMG Laboratories) according to the
manufacturer's instructions. β-galactosidase was meas-
ured using a spectrophotometric assay [37]. Relative luci-
ferase activity was calculated from the ratio between
relative light units produced from luciferase assays and
the absorbance at 405 nm for the β-galactosidase assays
after correction for the appropriate blank values. All val-
ues were normalised to the wild type construct that was
arbitrarily set at 100%.
Chromatin immunoprecipitation (ChIP) assays
MDA MB 231 cells were grown for 3 days to approxi-
mately 95% confluence in 150 mm tissue culture dishes.
The cells were exposed to a single dose of Adriamycin (5
µM) for 1 h [18]. Extractions were carried out at time 0 h
(control, unexposed cells) and 2 and 24 hours after expo-
sure.
Cells for each time course were then washed once with
PBS (room temperature) and fixed with 1% formaldehyde
in PBS (0.14 M NaCl, 2.7 mM KCl, 4.3 mM
NaHPO42H2O pH 7.2) at 37°C for 10 min, after which
they were rinsed twice with ice-cold PBS, scraped, and
resuspended in 1 mL of ice-cold PBS. Nuclei were col-
lected by centrifugation at 3000 rpm for 2 minutes at 4°C
and the resultant pellet was resuspended in 300 µL of lysis
buffer (1% SDS, 5 mM EDTA, 50 mM Tris.HCl, pH 8.1,
plus 1× Complete™ mini protease inhibitor [Roche]) then
incubated on ice for 10 min. This was followed by sonica-
tion (VirSonic Cell Disrupter, VirTis Company) three
times at 10% power for 15 sec each to produce fragments
in the range of 300–400 bp. After centrifugation the
supernatant was diluted (1:10) in buffer (1% Triton X-
100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris.HCl, pH
8.1, 1× Complete™ mini protease inhibitor cocktail
[Roche]).
Immunoclearing was performed by incubating soluble
chromatin with sheared herring sperm DNA (2 mg/ml),
20 µL pre-immune serum and 45 µL of 50% slurry protein
A/G plus-agarose beads (Santa Cruz) for 2 h at 4°C. After
centrifugation 1 µL (200 mg/mL) of specific antibodies
for Sp1 and Sp3 (Santa Cruz) were added to the superna-
tant and incubated overnight at 4°C. This was followed by
the addition of 45 µL protein A/G plus-agarose beads
(Sigma), herring sperm DNA and incubation for another
1 h at 4°C. Beads were harvested and washed sequentially
for 10 min in 1 mL each of TSE I (0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 20 mM Tris.HCl, pH 8.1, 150 mM
NaCl), TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris.HCl, pH 8.1, 500 mM NaCl), buffer III (0.25
M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10
mM Tris.HCl, pH 8.1), and 1× TE buffer.
The DNA-protein complex was eluted with 100 µL elution
buffer (1% SDS, 0.1 M NaHCO3) at room temperature for
10 minutes. The eluate was heated at 65°C to reverse for-
maldehyde cross-links and DNA extracted using a PCR
purification kit (QIAGEN) according to the manufac-
turer's instructions.
Quantification of ChIP assays
Quantification of ChIP products was carried out with real-
time PCR using a LightCycler (Roche) and the LightCycler
FastStart DNA MasterPLUS SYBR Green kit (Roche). Primers
were designed for the GC1 (GCCGTTCATAGGTGGA for-
ward and CGACTAAACAGGCAGGA reverse) and GC2
(TGCTGCGAATACAGACT forward and CTGACGTTGT-
TAGCGAG reverse) regions in the topoisomerase IIα pro-
moter using LightCycler Probe Design software (Roche) as
per the manufacturer's instructions. Real-time PCR proto-
cols were carried out according to the LightCycler manu-
facturer's instructions. Standard curves for relative
quantification were calculated using 1:1, 1:10, 1:100, and
1:1000 dilutions of input sample. The amounts of DNA
template for input and immunoprecipitated samples for
quantification were equivalent as measured by absorb-
ance at 260 nm. Amplification efficiency was corrected
using RelQuant V1.01 software from Roche.
Protein extraction
Cells were grown to 90% confluence washed in 1× PBS (8
g/L NaCl, 0.2 g/L KCl, 1.15 g/L Na2HPO4·7H2O pH 7.2)
and harvested in TEN (40 mM Tris-HCl, pH 7.9, 1 mM
EDTA, 0.15 M NaCl) buffer. The cells were lysed in extrac-
tion buffer (40 mM Hepes pH 7.9, 0.4 M KCl, 1 mM DTT,
10% glycerol, 1 mM EDTA, and 1× Roche Complete™
mini protease inhibitor) using three freeze-thaw cycles in
liquid nitrogen. Whole cell extracts had protein concen-
trations between 1 and 3 µgmL-1.
Immunoblotting
Protein extracts (~40 µg) were denatured by boiling for
five minutes in the presence of SDS and β-mercaptoetha-
nol and then incubated on ice for a further five minutes.
The samples were then loaded onto 10% SDS-PAGE mini
gels and run in 1× electrophoresis buffer (25 mM Tris, 192
mM Glycine, 0.1% w/v SDS in H2O) at 120 V for approx-
imately one hour [38-40]. Proteins were transferred to aBMC Molecular Biology 2007, 8:36 http://www.biomedcentral.com/1471-2199/8/36
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positively charged nylon membrane (Roche) in transfer
buffer (25 mM Tris, 192 mM glycine in H2O) at a constant
current of 450 mA for 45 minutes. Immuno-detection was
performed with BM Chemiluminescence Blotting Sub-
strate (POD) according to the manufacturer's recommen-
dations (Roche). Membranes were cut into regions
representing appropriate molecular weights for each pro-
tein and incubated in TBST (0.5 M Tris, 150 mM NaCl,
0.1% v/v Tween 20) including blocking reagent (5% non-
fat skim milk in TBST) overnight at 4°C with gentle shak-
ing. Immunodetection was carried out using 1:1000 dilu-
tion of Sp1 and Sp3 (Santa Cruz), 1:250 topoisomerase
IIα (Santa Cruz), and 1:2000 alpha tubulin (DM 1A)
(Sigma) primary antibodies in blocking reagent (2.5%
non-fat skim milk in TBST) for three hours at room tem-
perature with shaking.
Membranes were washed three times in TBST for 10 min-
utes at room temperature. A 1:5000 dilution of horserad-
ish peroxidase conjugated secondary antibody (anti-
rabbit, anti-goat or anti-mouse, (Sigma)) was added to
2.5% non-fat skim milk in TBST and incubated for 45
minutes at room temperature. Subsequently, the mem-
branes were washed in TBST three times for 15 min before
being immersed in detection solution (99:1 ratio of solu-
tion A to B) for two minutes at room temperature. Immu-
noblots were then detected and quantified using a LAS
1000 Darkbox (Fuji) and Scion Image 4.0.2 (Scion Corpo-
ration)
Chromosome conformation capture (3C) assay
The chromosome conformation capture assay [14] was
performed using HeLa cells. Cells were grown to 95% con-
fluence for 3 days and chromatin-crosslinked in buffer
(10 mM Tris-Cl pH 7.9, 10 mM MgCl2, 50 mM NaCl, 1
mM dithiothreitol) containing 1% formaldehyde for 10
minutes at room temperature. The addition of 0.125 M
glycine quenched the reaction before SDS was added to a
final concentration of 0.1%. This was followed by
removal of non-crosslinked proteins from DNA through
incubation at 37°C for 10 minutes. On completion of the
incubation, Triton X-100 was added to a final concentra-
tion of 1%.
The DNA (5 µL of ~400 ng/µL) was digested with the
restriction enzyme Bsu36I (Bio-Labs) overnight at 37°C in
a final volume of 50 µL. Restriction enzyme inactivation
was carried out with the addition of 1.6% SDS and incu-
bation at 65°C for 20 minutes. The reaction was then
diluted 15 times and Triton X-100 was added to 1%. The
DNA was then ligated for 30 minutes at room temperature
using T4 DNA ligase. Crosslinking was reversed by over-
night incubation at 65°C in the presence of 5 mg/mL Pro-
teinase K. The ligated (or control) product was then
amplified by PCR and detected on a 1.5% agarose gel. The
forward (TACTTTTATTTCTTTGAAA) and reverse
(ACAAATCAGCGAAAGT) primers used for PCR were spe-
cific for the human topoisomerase IIα promoter.
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